Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: A novel treatment option

Gynecological Endocrinology

Volumn 29, Issue 9, 2013, Pages 811-816

  Gadducci, Angiolo ^a   Sergiampietri, Claudia ^a   Guiggi, Ilaria ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Aflibercept; Antiangiogenic therapy; Bevacizumab; Dovitinib; Endometrial cancer; FGFR; VEGF

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CISPLATIN; DOVITINIB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEFITINIB; IRINOTECAN; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TRASTUZUMAB; VASCULOTROPIN;

ADJUVANT CHEMORADIOTHERAPY; ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER INHIBITION; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CARCINOMA; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; RECURRENT DISEASE; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY;

EID: 84883436058     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2013.801446     Document Type: Article

References (70)

1. Prat J, Gallardo A, Cuatrecasas M, Catasús L. Endometrial carcinoma: Pathology and genetics. Pathology 2007;39:72-87
2. Benedetti Panici P, Basile S, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: Randomized clinical trial. J Natl Cancer Inst 2008;100: 1707-16
3. Kitchener H, Swart AM, Qian Q, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): A randomised study. Lancet 2009;373:125-36
4. May K, Bryant A, Dickinson HO, et al. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev 2010;1:CD007585
5. Galaal K, Bryant A, Fisher AD, et al. Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database Syst Rev 2012;9:CD006655
6. Kilgore JE, Jackson AL, Ko EM, et al. Recurrence-free and 5-year survival following robotic-Assisted surgical staging for endometrial carcinoma. Gynecol Oncol 2013;129:49-53
7. Gadducci A, Cosio S, Landoni F, et al. Analysis of treatment failures and survival of patients with uterine papillary serous carcinoma: A Cooperation Task Force (CTF) Study. Int J Gynecol Cancer 2012;22: 1355-60
8. Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev 2012;4:CD003916
9. Nout RA, Putter H, Jürgenliemk-Schulz IM, et al. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer 2012;48: 1638-48
10. Gadducci A, Greco C. The evolving role of adjuvant therapy in endometrial cancer. Crit Rev Oncol Hematol 2011;78:79-91
11. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-Abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2006;24:36-44
12. Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: Results of a randomised trial. Br J Cancer 2006;95:266-71
13. Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies. Eur J Cancer 2010;46:2422-31
14. Gadducci A, Cosio S, Genazzani AR. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol 2006;58:242-56
15. Xiong Y, Dowdy SC, Gonzalez Bosquet J, et al. Epigeneticmediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. Gynecol Oncol 2005;99:135-41
16. Ren Y, Liu X, Ma D, et al. Down-regulation of the progesterone receptor by the methylation of progesterone receptor gene in endometrial cancer cells. Cancer Genet Cytogenet 2007;175: 107-16
17. Yang S, Thiel KW, De Geest K, Leslie KK. Endometrial cancer: Reviving progesterone therapy in the molecular age. Discov Med 2011;12:205-12
18. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2004;22:2159-66
19. Vale CL, Tierney J, Bull SJ, Symonds PR. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev 2012;8:CD003915
20. Delmonte A, Sessa C. Molecule-targeted agents in endometrial cancer. Curr Opin Oncol. 2008;20:554-59
21. Slomovitz BM, Lu KH, Johnston T, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 2010;116:5415-19
22. Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: A trial of the NCIC Clinical Trials Group. J Clin Oncol 2011;29:3278-85
23. Oza AM, Eisenhauer EA, Elit L, et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 2008;26:4319-25
24. Leslie KK, Sill MW, Darcy KM, et al. Efficacy and safety of gefitinib (Iressa, ZD1839) and potential prognostic value of soluble EGFR, EGFR mutations and tumor markers in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. J Clin Oncol 2009;27:abstr e16542
25. Santin AD, Bellone S, Roman JJ, et al. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynaecol Obstet 2008;102:128-31
26. Fleming GF, Sill MW, Darcy KM, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2010;116:15-20
27. Kamat AA, Merritt WM, Coffey D, et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 2007;13:7487-95
28. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76
29. Chen CA, Cheng WF, Lee CN, et al. Cytosol vascular endothelial growth factor in endometrial carcinoma: Correlation with diseasefree survival. Gynecol Oncol 2001;80:207-12
30. Giatromanolaki A, Sivridis E, Brekken R, et al. The angiogenic ''vascular endothelial growth factor/flk-1(KDR) receptor'' pathway in patients with endometrial carcinoma: Prognostic and therapeutic implications. Cancer 2001;92:2569-77
31. Hirai M, Nakagawara A, Oosaki T, et al. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial cancer. Gynecol Oncol 2001;80:181-8
32. Talvensaari-Mattila A, Soini Y, Santala M. VEGF and its receptors (flt-1 and KDR/flk-1) as prognostic indicators in endometrial carcinoma. Tumour Biol 2005;26:81-7
33. Pengchong H, Tao H. Expression of IGF-1R, VEGF-C and D2-40 and their correlation with lymph node metastasis in endometrial adenocarcinoma. Eur J Gynaecol Oncol 2011;32:660-4
34. Gadducci A, Cosio S, Genazzani AR. Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer. Crit Rev Oncol Hematol 2011;80:181-92
35. Mena AC, Pulido EG, Guillen-Ponce C. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: Sunitinib. Anticancer Drugs 2010;21:S3-11
36. Correa R, Mackay H, Hirte HW, et al. A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia. J Clin Oncol 2010;28: Abstr 5038
37. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
38. Nimeiri HS, Oza AM, Morgan RJ, et al. Sorafenib (SOR) in patients (pts) with advanced/recurrent uterine carcinoma (UCA) or carcinosarcoma (CS): A phase II trial of the University of Chicago, PMH, and California Phase II Consortia. J Clin Oncol 2008;26:abstr 5585
39. Eisen T, Boshoff C, Mak I, et al. Continuous low dose Thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000;82:812-17
40. Melchert M, List A. The thalidomide saga. Int J Biochem Cell Biol 2007;39:1489-99
41. McMeekin DS, Sill MW, Benbrook D, et al. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study. Gynecol Oncol 2007;105:508-16
42. McMeekin DS, Sill MW, Darcy KM, et al. A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: A Gynecologic Oncology Group study. Gynecol Oncol. 2012;127:356-61
43. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400
44. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2007;25:5165-71
45. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-6
46. Tanyi JL, McCann G, Hagemann AR, et al. Clinical predictors of bevacizumab-Associated gastrointestinal perforation. Gynecol Oncol 2011;120:464-9
47. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-83
48. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-96
49. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:2039-45
50. Pujade-Lauraine E, Hilpert F, Weber B, et al. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 2012;30:abstr LBA 5002
51. Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. J Clin Oncol 2011;29:2259-65
52. Kuo CJ, Farnebo F, Yu EY, et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci U S A 2001;98:4605-10
53. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002;99:11393-8
54. Tew WP, Gordon M, Murren J, et al. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res 2010;16:358-66
55. Rudge JS, Holash J, Hylton D, et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci USA. 2007;104:18363-70
56. Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: Drug targets for anti-Angiogenic therapy? Nat Rev Cancer 2008;8:942-56
57. Byrne AT, Ross L, Holash J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003;9:5721-8
58. Gotlieb WH, Amant F, Advani S, et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: A phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2012;13:154-62
59. Sideras K, Dueck AC, Hobday TJ, et al. North central cancer treatment group (NCCTG) N0537: Phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane. Clin Breast Cancer 2012;12: 387-91
60. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30:3499-506
61. Mackay HJ, Buckanovich RJ, Hirte H, et al. A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. Gynecol Oncol 2012;125: 136-40
62. Sharma T, Dhingra R, Singh S, et al. Aflibercept: A novel VEGF targeted agent to explore the future perspectives of anti-Angiogenic therapy for the treatment of multiple tumors. Mini Rev Med Chem 2013;13:530-40
63. Coleman RL, Sill MW, Lankes HA, et al. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2012; 127:538-43
64. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-65
65. Pollock PM, Gartside MG, Dejeza LC, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007;26:7158-62
66. Dutt A, Salvesen HB, Chen TH, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 2008; 105:8713-17
67. Byron SA, Pollock PM. FGFR2 as a molecular target in endometrial cancer. Future Oncol 2009;5:27-32
68. Dey JH, Bianchi F, Voshol J, et al. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 2010;70:4151-62
69. Sivanand S, Penä-Llopis S, Zhao H, et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med 2012;4:137-75
70. Kim KB, Chesney J, Robinson D, et al. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res 2011;17:7451-61